Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction
Alessio Alogna(Deutsches Herzzentrum der Charité), Barry A. Borlaug(Mayo Clinic in Arizona), James L. Kirkland(Mayo Clinic in Florida), Mark C. Petrie(Copenhagen University Hospital), Hidemi Sorimachi(Mayo Clinic), Margaret M. Redfield(Mayo Clinic), Tamar Tchkonia(Mayo Clinic in Arizona), Katlyn E. Koepp(Mayo Clinic), Carolyn S.P. Lam, Michael S. Sabbah(Mayo Clinic), Adriaan A. Voors, Paul M. Ridker(Brigham and Women's Hospital), Masaru Obokata(Mayo Clinic), Jair Machado Espindola Netto(Mayo Clinic), Michael D. Jensen(Mayo Clinic in Florida)
Cited by 111
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
|Journal of the American College of Cardiology|2013|4k